Janus Henderson Group PLC Has $84.85 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Janus Henderson Group PLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 20.3% during the 1st quarter, HoldingsChannel reports. The fund owned 8,908,506 shares of the biotechnology company’s stock after buying an additional 1,504,120 shares during the quarter. Janus Henderson Group PLC’s holdings in BioCryst Pharmaceuticals were worth $84,854,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares during the period. Cetera Investment Advisers boosted its stake in BioCryst Pharmaceuticals by 13.8% in the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,494 shares in the last quarter. Captrust Financial Advisors boosted its stake in BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 1,527 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares during the period. Finally, Legato Capital Management LLC raised its stake in BioCryst Pharmaceuticals by 10.0% during the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 2,172 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.8%

BCRX stock opened at $8.98 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22. The firm has a market cap of $2.28 billion, a PE ratio of -5.04 and a beta of 0.55. The business’s 50-day moving average price is $9.30 and its two-hundred day moving average price is $8.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.20 EPS. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

BCRX has been the topic of several research analyst reports. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Citizens Jmp upped their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.80.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.